<ѻý>Positive Results for Odronextamab in Relapsed/Refractory DLBCLѻý> But experts aren't sure where it would fit in with currently approved bispecifics Dec 20, 2023 video
<ѻý>'Curable': A Case for Precision of Languageѻý> Patients need a clear description of their prognosis Dec 19, 2023
<ѻý>Psilocybin May Help Ease Depression in Cancer Patientsѻý> In small trial, half had early remission of depressive symptoms after psilocybin-assisted therapy Dec 18, 2023
<ѻý>National Database Study Finds Higher Risk for Barrett’s Esophagus in IBDѻý> But no greater chance of BE-tied malignancy for these patients Dec 16, 2023
<ѻý>The 'Before and After': An Eye Surgeon's Unexpected Findingѻý> There are a few possible diagnoses in patient with headaches, blurred vision, but one stands out Dec 16, 2023
<ѻý>FDA Approves New First-Line Standard of Care in Bladder Cancerѻý> Enfortumab vedotin plus pembrolizumab doubled survival as compared with chemotherapy Dec 15, 2023
<ѻý>JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphomaѻý> Phase II findings on golidocitinib will form the basis of an accelerated approval application Dec 15, 2023
<ѻý>Hematocrit Stabilized in Polycythemia Vera Treated With Novel Hepcidin Mimeticѻý> Rusfertide maintained hematocrit Dec 15, 2023
<ѻý>Atezolizumab Plus Carboplatin Boosts Survival in Metastatic TNBCѻý> But editorialists note that with recent advances, "it is hard to justify" use of combination Dec 15, 2023
<ѻý>FDA Approves Belzutifan for Advanced Renal Cell Carcinomaѻý> HIF-2 inhibitor indicated for patients who progress after immunotherapy and anti-VEGF Dec 15, 2023
<ѻý>Why Some Myeloma Patients Refuse Stem Cell Transplantѻý> Study shows the various factors behind refusal of autologous stem cell transplantation Dec 15, 2023 video
<ѻý>'Exploding' Field of Antibody-Drug Conjugates Makes Inroads in Ovarian Cancerѻý> Our panel of experts discuss the latest data from various ongoing trials Dec 14, 2023 video
<ѻý>Andre Braugher's Cancer Dx; Malignancies Rising in Younger Adults; Negative Trialsѻý> News, features, and commentary about cancer-related issues Dec 14, 2023
<ѻý>FDA OKs Maintenance Option for High-Risk Neuroblastomaѻý> Eflornithine approved to reduce relapse risk in both kids and adults Dec 14, 2023
<ѻý>Ibrutinib-Venetoclax Improves PFS in R/R Mantle Cell Lymphomaѻý> Will results revive ibrutinib role in MCL following withdrawal of accelerated approval? Dec 13, 2023
<ѻý>'Half-Matched' BMTs Effective in Severe Sickle Cell Diseaseѻý> High survival rates observed in patients not normally suitable for transplant Dec 13, 2023
<ѻý>Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trialѻý> Numerical advantages in OS, PFS fall short of statistical significance Dec 13, 2023
<ѻý>Pomalidomide Cuts Severe Epistaxis in Genetic Bleeding Disorderѻý> 24 weeks of daily treatment significantly reduced recurrent nosebleeds in HHT trial Dec 13, 2023
<ѻý>Early Detection Is Key to Higher Cure Rates in Ovarian Cancerѻý> "We are not aware of precancer stages for ovarian cancer" Dec 13, 2023
<ѻý>Four Drugs Top Three for Upfront Treatment of Multiple Myelomaѻý> Adding anti-CD38 antibodies boosts response and PFS, but timing, sequencing, cost questioned Dec 13, 2023
<ѻý>One in Five BRCA-Positive Breast Cancer Patients Able to Conceiveѻý> Disease-free survival comparable between patients who did and did not become pregnant Dec 12, 2023
<ѻý>Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemiaѻý> Investigational drug revumenib now under review at FDA for KMT2A-rearranged disease Dec 12, 2023
<ѻý>Novel Monoclonal Antibody Reduces Bleeds in Hemophilia A and Bѻý> Marstacimab reduced the annualized bleeding rate versus on-demand, prophylactic treatments Dec 12, 2023
<ѻý>Ruxolitinib Combinations Reduce Spleen Volume in Myelofibrosisѻý> Combos with navitoclax or pelabresib led to more patients achieving reductions Dec 12, 2023
<ѻý>KEYNOTE-A18 Data Are 'Practice-Changing' for Cervical Cancerѻý> Domenica Lorusso details the importance of modern radiotherapy in this regimen Dec 12, 2023
<ѻý>Axatilimab Shows Efficacy in Recurrent/Refractory GVHDѻý> Highest overall response rate and least toxicity seen with lowest dose Dec 11, 2023
<ѻý>MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemiaѻý> No advantage for MRD-negative patients in first remission after induction, regardless of FLT3 ITD Dec 11, 2023
<ѻý>A Closer Look at the Approval of CRISPR/Cas9 Gene Therapy for Sickle Cell Diseaseѻý> This landmark event brings up broader considerations and implications for other diseases Dec 11, 2023
<ѻý>ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remissionѻý> Better 2-year PFS, OS, but not applicable to primary refractory disease Dec 10, 2023
<ѻý>Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patientsѻý> Time-limited approach based on MRD response outperforms FCR, but U.S. applicability unclear Dec 10, 2023
<ѻý>Emicizumab Safe, Effective, in Infants With Hemophilia Aѻý> More than half of children in study had no treated bleeds at follow-up of more than 100 weeks Dec 10, 2023
<ѻý>Add-On Inavolisib Ups PFS in PIK3CA-Mutated Breast Cancerѻý> Triplet therapy may surpass benefits of current "pretty active doublet" therapy, expert says Dec 10, 2023
<ѻý>Lovo-Cel 'Life-Changing, Transformative' in Sickle Cell Diseaseѻý> Near complete resolution of pain events in patients, including adolescents Dec 10, 2023
<ѻý>Bispecific Antibody Combination Active in Metastatic HR+/HER2+ Breast Cancerѻý> Two-thirds of patients progression free at 6 months with zanidatamab, palbociclib, fulvestrant Dec 10, 2023
<ѻý>Grappling With Our Deadliest Cancerѻý> Here are essential steps to improve lung cancer screening Dec 10, 2023
<ѻý>Benefits of Myeloma Regimens in the Real World Fall Well Short of Trialsѻý> Survival 75% worse compared with outcomes seen in registrational studies Dec 10, 2023
<ѻý>Completely Oral Regimen Effective, Feasible in APLѻý> 97% of patients alive and relapse-free at 3 years Dec 10, 2023
<ѻý>Less-Frequent Surveillance Mammo Feasible in Older Breast Cancer Survivorsѻý> No difference for survival outcomes for annual versus around every 2 years Dec 09, 2023
<ѻý>AI and Breast Cancer Screening; Cancer After Treatment for Sickle Cellѻý> Also in TTHealthWatch: mail-in cervical cancer screening kits Dec 09, 2023 podcast
<ѻý>Bilateral Mastectomy Not Tied to Better Survival in BRCA1-Positive Breast Cancerѻý> However, the surgery did reduce risk of contralateral breast cancer Dec 09, 2023